Trial Profile
A Dose-Escalating Phase I Study for Safety and Tolerability of Bevacizumab in Collagen Delivery Vehicle Administered Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 14 Jul 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 11 Jul 2017 Status changed from recruiting to discontinued.
- 10 Feb 2012 New trial record